JP2016501020A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501020A5 JP2016501020A5 JP2015544499A JP2015544499A JP2016501020A5 JP 2016501020 A5 JP2016501020 A5 JP 2016501020A5 JP 2015544499 A JP2015544499 A JP 2015544499A JP 2015544499 A JP2015544499 A JP 2015544499A JP 2016501020 A5 JP2016501020 A5 JP 2016501020A5
- Authority
- JP
- Japan
- Prior art keywords
- segment
- seq
- virus
- influenza
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261732809P | 2012-12-03 | 2012-12-03 | |
| US61/732,809 | 2012-12-03 | ||
| PCT/EP2013/075294 WO2014086732A2 (en) | 2012-12-03 | 2013-12-02 | Influenza virus reassortment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016501020A JP2016501020A (ja) | 2016-01-18 |
| JP2016501020A5 true JP2016501020A5 (enExample) | 2017-01-19 |
| JP6421128B2 JP6421128B2 (ja) | 2018-11-07 |
Family
ID=49713076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015544499A Active JP6421128B2 (ja) | 2012-12-03 | 2013-12-02 | リアソータントインフルエンザａウイルス |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9708585B2 (enExample) |
| EP (1) | EP2925356A2 (enExample) |
| JP (1) | JP6421128B2 (enExample) |
| KR (1) | KR20150110494A (enExample) |
| CN (1) | CN105120893B (enExample) |
| AU (2) | AU2013354219A1 (enExample) |
| BR (1) | BR112015012380A2 (enExample) |
| CA (1) | CA2893429A1 (enExample) |
| HK (1) | HK1214959A1 (enExample) |
| MX (1) | MX2015006927A (enExample) |
| WO (1) | WO2014086732A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013354219A1 (en) * | 2012-12-03 | 2015-07-02 | Novartis Ag | Reassortant influenza a viren |
| WO2016172588A1 (en) * | 2015-04-24 | 2016-10-27 | Andrew Cox | Attenuated influenza vaccines and uses thereof |
| AU2016281904B2 (en) | 2015-06-26 | 2022-08-11 | Seqirus UK Limited | Antigenically matched influenza vaccines |
| GB201602535D0 (en) * | 2016-02-12 | 2016-03-30 | Univ Edinburgh | Improved flu vaccine yield |
| WO2019044636A1 (ja) * | 2017-08-28 | 2019-03-07 | 一般財団法人阪大微生物病研究会 | リアソータントインフルエンザウイルスの段階的作出方法 |
| WO2019086463A1 (en) | 2017-10-30 | 2019-05-09 | Baxalta GmbH | Environmentally compatible detergents for inactivation of lipid-enveloped viruses |
| CN111315407B (zh) * | 2018-09-11 | 2023-05-02 | 上海市公共卫生临床中心 | 一种广谱抗流感疫苗免疫原及其应用 |
| KR101954904B1 (ko) | 2018-10-15 | 2019-03-06 | 남종규 | 복층의 태양광 설치 구조 |
| CN111647610B (zh) * | 2020-06-02 | 2021-09-03 | 扬州大学 | 一种互换ha和ns1缺失基因包装信号的h9n2亚型禽流感病毒及其构建方法和应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
| AU5543294A (en) | 1993-10-29 | 1995-05-22 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
| DE19612967A1 (de) | 1996-04-01 | 1997-10-02 | Behringwerke Ag | Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren |
| DE19612966B4 (de) | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
| TW570803B (en) | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
| US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
| EP1098961B1 (en) | 1998-06-12 | 2008-01-16 | Mount Sinai School Of Medicine Of The City University Of New York | Interferon inducing genetically engineered attenuated viruses |
| AR025750A1 (es) | 1999-09-24 | 2002-12-11 | Smithkline Beecham Biolog | Vacunas |
| WO2001064846A1 (fr) | 2000-03-03 | 2001-09-07 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Cellule utilisable pour culture sans serum et culture en suspension, et procede de production de virus pour vaccin utilisant cette cellule |
| GB0024089D0 (en) | 2000-10-02 | 2000-11-15 | Smithkline Beecham Biolog | Novel compounds |
| US20040071734A1 (en) | 2001-02-23 | 2004-04-15 | Nathalie Garcon | Novel vaccine |
| WO2002067983A1 (en) | 2001-02-23 | 2002-09-06 | Glaxosmithkline Biologicals S.A. | Novel vaccine |
| TWI228420B (en) | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
| WO2005097181A1 (en) | 2004-04-05 | 2005-10-20 | Pfizer Products Inc. | Microfluidized oil-in-water emulsions and vaccine compositions |
| WO2005113756A1 (en) | 2004-05-14 | 2005-12-01 | Glaxosmithkline Biologicals S.A. | Method |
| US20080254067A1 (en) | 2004-05-20 | 2008-10-16 | Id Biomedical Corporation | Process for the Production of an Influenza Vaccine |
| CN103555670B (zh) | 2004-12-23 | 2015-08-12 | 米迪缪尼有限公司 | 用于病毒增殖的非致瘤性mdck细胞系 |
| US7691368B2 (en) | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
| CA2613283A1 (en) | 2005-06-21 | 2007-01-04 | Medimmune Vaccines, Inc. | Methods and compositions for expressing a heterologous protease |
| US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
| ES2359214T5 (es) | 2005-11-01 | 2014-10-08 | Novartis Vaccines And Diagnostics Gmbh | Vacunas virales derivadas de células con niveles reducidos de ADN celular residual por tratamiento con beta-propiolactona |
| BRPI0618254A2 (pt) | 2005-11-04 | 2011-08-23 | Novartis Vaccines & Diagnostic | emulsões com agente tensoativo de fase aquosa livre para fornecer adjuvante às vacinas contra influenza dividido |
| FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
| JP2009532352A (ja) * | 2006-03-31 | 2009-09-10 | ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション | ワクチンのための高力価組み換えインフルエンザ・ウィルス |
| JP5491173B2 (ja) | 2006-04-19 | 2014-05-14 | メディミューン，エルエルシー | イヌ細胞中でマイナス鎖ウイルスｒｎａを発現させるための方法および組成物 |
| PT2086582E (pt) | 2006-10-12 | 2013-01-25 | Glaxosmithkline Biolog Sa | Vacina compreendendo uma emulsão adjuvante óleo em água |
| CN101553252A (zh) | 2006-12-06 | 2009-10-07 | 诺华有限公司 | 包含来自于四株流感病毒的抗原的疫苗 |
| WO2008157419A2 (en) * | 2007-06-13 | 2008-12-24 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunogenic peptides of influenza virus |
| EP2045323A1 (en) | 2007-10-05 | 2009-04-08 | Avir Green Hills Biotechnology Research Development Trade Ag | Linear expression constructs for production of influenza virus particles |
| ES2675771T3 (es) * | 2008-12-16 | 2018-07-12 | Ology Bioservices, Inc. | Producción de vacunas contra el virus de la gripe |
| EP2233152A1 (en) | 2009-03-24 | 2010-09-29 | Avir Green Hills Biotechnology Research Development Trade Ag | High growth reassortant influenza A virus |
| EP2401384B1 (en) | 2009-05-21 | 2012-10-03 | Novartis AG | Reverse genetics using non-endogenous pol i promoters |
| EP2448598B1 (en) * | 2009-06-25 | 2016-03-30 | MedImmune, LLC | Swine influenza hemagglutinin variants |
| CN102666860B (zh) | 2009-07-31 | 2015-06-17 | 诺华股份有限公司 | 反向遗传系统 |
| JP5876036B2 (ja) * | 2010-05-21 | 2016-03-02 | ノバルティス アーゲー | インフルエンザウイルス再集合方法 |
| FR2962739B1 (fr) * | 2010-07-13 | 2014-01-31 | Univ Claude Bernard Lyon | Souches virales modifiees et procede pour ameliorer la production de semences vaccinales de virus influenza |
| AU2013354219A1 (en) * | 2012-12-03 | 2015-07-02 | Novartis Ag | Reassortant influenza a viren |
-
2013
- 2013-12-02 AU AU2013354219A patent/AU2013354219A1/en not_active Abandoned
- 2013-12-02 HK HK16102968.6A patent/HK1214959A1/zh unknown
- 2013-12-02 CA CA2893429A patent/CA2893429A1/en not_active Abandoned
- 2013-12-02 MX MX2015006927A patent/MX2015006927A/es unknown
- 2013-12-02 CN CN201380071503.1A patent/CN105120893B/zh active Active
- 2013-12-02 WO PCT/EP2013/075294 patent/WO2014086732A2/en not_active Ceased
- 2013-12-02 EP EP13799527.0A patent/EP2925356A2/en not_active Withdrawn
- 2013-12-02 KR KR1020157016758A patent/KR20150110494A/ko not_active Ceased
- 2013-12-02 BR BR112015012380A patent/BR112015012380A2/pt not_active IP Right Cessation
- 2013-12-02 US US14/648,886 patent/US9708585B2/en active Active
- 2013-12-02 JP JP2015544499A patent/JP6421128B2/ja active Active
-
2017
- 2017-06-13 US US15/621,270 patent/US10500266B2/en active Active
-
2018
- 2018-09-19 AU AU2018232956A patent/AU2018232956B2/en active Active
-
2019
- 2019-10-28 US US16/665,104 patent/US20200155666A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016501020A5 (enExample) | ||
| JP2016509864A5 (enExample) | ||
| JP2015119730A5 (enExample) | ||
| Milián et al. | Current and emerging cell culture manufacturing technologies for influenza vaccines | |
| Thomas et al. | Cell-mediated protection in influenza infection | |
| Cauldwell et al. | Viral determinants of influenza A virus host range | |
| Zhou et al. | Characterization of uncultivable bat influenza virus using a replicative synthetic virus | |
| Horimoto et al. | Enhanced growth of seed viruses for H5N1 influenza vaccines | |
| Bissinger et al. | Semi-perfusion cultures of suspension MDCK cells enable high cell concentrations and efficient influenza A virus production | |
| JP2019011344A5 (enExample) | ||
| Chen et al. | The impact of key amino acid substitutions in the hemagglutinin of influenza A (H3N2) viruses on vaccine production and antibody response | |
| Petiot et al. | Influenza viruses production: Evaluation of a novel avian cell line DuckCelt®-T17 | |
| Feng et al. | Equine and canine influenza H3N8 viruses show minimal biological differences despite phylogenetic divergence | |
| JP2012511914A5 (enExample) | ||
| Jang et al. | Principles underlying rational design of live attenuated influenza vaccines | |
| JP2013179943A5 (enExample) | ||
| WO2008156681A2 (en) | Adenoviral vectors for influenza virus production | |
| Li et al. | Screening of the high yield influenza B virus on MDCK cell and cloning of its whole genome | |
| Abdoli et al. | Comparison between MDCK and MDCK-SIAT1 cell lines as preferred host for cell culture-based influenza vaccine production | |
| Johnson et al. | Identification of influenza A/PR/8/34 donor viruses imparting high hemagglutinin yields to candidate vaccine viruses in eggs | |
| Silva et al. | Recent advances and current challenges in process intensification of cell culture‐based influenza virus vaccine manufacturing | |
| Mostafa et al. | Efficient generation of recombinant influenza a viruses employing a new approach to overcome the genetic instability of HA segments | |
| Mostafa et al. | The PB1 segment of an influenza A virus H1N1 2009pdm isolate enhances the replication efficiency of specific influenza vaccine strains in cell culture and embryonated eggs | |
| Barman et al. | Manipulation of neuraminidase packaging signals and hemagglutinin residues improves the growth of A/Anhui/1/2013 (H7N9) influenza vaccine virus yield in eggs | |
| CN104195154A (zh) | 新城疫病毒Mukteswar中等毒力疫苗株反向遗传操作系统及其应用 |